# Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma

> **NCT01655693** · PHASE3 · COMPLETED · sponsor: **Valerio Therapeutics** · enrollment: 397 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Doxorubicin 20 mg/m2
- **DRUG:** Doxorubicin 30 mg/m2
- **DRUG:** Best Standard of Care

## Key facts

- **NCT ID:** NCT01655693
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2017-05
- **Final completion:** 2019-05
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01655693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01655693, "Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01655693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*